Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to "Overweight" at Piper Sandler

Key Points

• Supernus Pharmaceuticals was upgraded to an "overweight" rating by Piper Sandler, with a new target price set at $65.00, indicating a potential upside of 35.42% from its current price.
• While Piper Sandler has a positive outlook, other analysts have given mixed ratings, with Wall Street Zen downgrading the stock to a "hold" and Zacks raising it to "strong-buy."
• Insider activity includes significant share sales, with the SVP and Director selling thousands of shares, collectively worth over $500,000 in the last few months.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was upgraded by research analysts at Piper Sandler from a "neutral" rating to an "overweight" rating in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has a $65.00 target price on the specialty pharmaceutical company's stock, up from their previous target price of $40.00. Piper Sandler's price target indicates a potential upside of 35.42% from the company's current price.

Several other research analysts have also commented on the stock. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, October 3rd. Weiss Ratings reissued a "hold (c)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday. Zacks Research raised shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 17th. Finally, Cantor Fitzgerald lifted their price target on shares of Supernus Pharmaceuticals from $46.00 to $63.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 30th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $64.00.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $48.00 on Thursday. The firm has a 50 day simple moving average of $44.40 and a 200-day simple moving average of $36.44. Supernus Pharmaceuticals has a one year low of $29.16 and a one year high of $49.66. The firm has a market cap of $2.69 billion, a price-to-earnings ratio of 41.74 and a beta of 0.78.

Insider Activity at Supernus Pharmaceuticals

In other news, SVP Frank Mottola sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction on Friday, September 12th. The shares were sold at an average price of $45.87, for a total value of $229,350.00. Following the transaction, the senior vice president directly owned 15,496 shares of the company's stock, valued at $710,801.52. The trade was a 24.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Frederick M. Hudson sold 7,457 shares of the business's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $42.26, for a total transaction of $315,132.82. Following the completion of the transaction, the director directly owned 46,307 shares in the company, valued at $1,956,933.82. This represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 302,841 shares of company stock worth $13,361,449 over the last 90 days. 8.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new position in Supernus Pharmaceuticals in the 1st quarter valued at $41,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Supernus Pharmaceuticals in the 1st quarter valued at $46,000. EverSource Wealth Advisors LLC acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth $51,000. Raymond James Financial Inc. acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth $55,000. Finally, Osaic Holdings Inc. grew its stake in shares of Supernus Pharmaceuticals by 211.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company's stock worth $63,000 after purchasing an additional 1,328 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.